What DIAN DIAGNOSTICS GROUP CO., LTD. does

DIAN Diagnostics Group Co., Ltd. is a Chinese independent clinical laboratory (ICL) operator and diagnostic product manufacturer headquartered in Hangzhou, Zhejiang, and listed on the Shenzhen Stock Exchange GEM (stock code 300244) since July 2011. The company runs an integrated "product + service" model that combines proprietary diagnostic kits and instruments (including DP-TOF mass spectrometry, LC-MS/MS systems, and HPV kits) with a national network of nearly 40 medical laboratories and 400+ collaborative laboratory projects deployed across 31 Chinese provinces. Customers include more than 22,000 medical institutions, with 90%+ coverage of secondary and tertiary hospitals in its core operating region and 60%+ of partner facilities classified as tertiary hospitals.

The company operates a high-throughput platform processing approximately 250,000 samples per day across 4,500+ diagnostic parameters, supported by 168 domestic and foreign qualifications and ISO 15189 implementation across 200+ hospitals. Its technology stack includes an AI-assisted digital pathology diagnosis solution (PathoAI, launched October 2022), virtual autopsy tools (Diangio & Aiangio), forensic services through 8 institutions, a health management arm (DIAN Healthcare), and cold chain logistics. A 10 PB clinical and pathology database underpins its AI and analytics work.

DIAN generates revenue through a combination of fee-for-service diagnostic testing on a volume basis, revenue-share arrangements with hospitals under collaborative laboratory agreements, and product sales of its proprietary instruments and kits. Long-standing partnerships with major industry players -- including Roche Diagnostics, Foundation Medicine, SCIEX/Danaher, Agena Bioscience, Phenomenex, and Johns Hopkins University -- reinforce the international component of its product and standards portfolio. The company has signaled international expansion through a Vietnam subsidiary (April 2024), a Malaysia representative office, a Gulf Medical University partnership in the UAE (January 2024), and existing operations in Germany and Australia.

Name

DIAN DIAGNOSTICS GROUP CO., LTD.

Legal name

DIAN DIAGNOSTICS Group Co., Ltd.

Website

https://en.dazd.cn

Company type

Public

Founded year

1996

Operating status

Operating

Headcount range

1–10 employees

Short description

DIAN Diagnostics is a Chinese integrated diagnostic services and product manufacturer operating ~40 labs across 31 provinces, serving 22,000+ medical institutions with 250,000 daily samples across 4,500+ parameters and a proprietary AI pathology platform.

Ownership category

akta.pro rank

Product category

Medical Diagnostic Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Medical and Diagnostic Laboratories (62151), Scientific Research and Development Services (5417)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD)

akta.pro secondary industries

Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges) (HLAHAOAI), Sample Logistics, Biorepository & IVD Kit Management (Trial Support) (HLAGAEAI), Quality, Peer Review & Compliance Tools (MQSA/ACR/QA) (HLACALAL), Medical Devices & Diagnostics Temperature-Controlled Storage (TLALABAH)

Keywords

• Medical diagnostic services
• Clinical laboratory testing
• Molecular diagnostics platforms
• Mass spectrometry diagnostics
• Digital pathology diagnostics

Headquarters

HQ city

Hangzhou

HQ country

China

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Diagnostic Services: Medical diagnostic services through nearly 40 medical laboratories network serving 22,000+ medical institutions with daily sample size of 250,000.
2. Diagnostic Product Manufacturing: Manufacturing and distribution of diagnostic products including laboratory supplies, kits, and instruments through channel subsidiaries.
3. Health Management: One-stop health management services from DIAN Healthcare covering physical examination, precision medicine, chronic disease treatment, and sub-health management.
4. Forensic Services: Third-party forensic institute with eight forensics chain institutions in China providing independent forensic services and products.
5. Medical Cold Chain Logistics: Cold chain storage and distribution services for medical devices, medicines, diagnostic and biological products through Zhejiang DIAN Shenhai Cold-Chain Logistics Co., Ltd.
6. Collaborative Laboratory Services: Consultation, management, and technical services for hospital testing centers and laboratories with over 400 collaborative projects.
7. Investment Returns: ZJH FUND (RMB 10 billion target fund) focusing on healthcare investments with Phase 1 RMB 1 billion completed, two projects listed on stock market.

Go-to-market motion4 records

Distribution channels5 records

Marketing channels5 records

Core offering

DIAN Diagnostics Group is an integrated medical diagnostics provider that delivers clinical diagnostic services through a network of nearly 40 medical laboratories serving more than 22,000 medical institutions in China with daily capacity for 250,000 samples. Alongside its service business, the company develops, manufactures and sells proprietary diagnostic products including the DP-TOF Nucleic Acid Mass Spectrometry Solution, LC MS/MS Solution, AI-Assisted Digital Pathology Diagnosis Solution, laboratory supplies and kits, and a Forensic Drug Test Solution. The offering is rounded out by health management services and a dedicated cold-chain logistics subsidiary (Zhejiang DIAN Shenhai).

Product overview

DIAN DIAGNOSTICS GROUP CO., LTD. operates as an integrated medical diagnostics platform with 'product + service' architecture. The company offers: (1) AI-Assisted Digital Pathology Diagnosis Solution for integrated digital pathology; (2) DP-TOF Nucleic Acid Mass Spectrometry Solution as China's first approved general-purpose nucleic acid mass spectrometer; (3) LC MS/MS Solution for biomarker identification; (4) comprehensive Forensic Drug Test Solutions including handheld detectors and immunoassay kits; (5) Laboratory Supplies and Kits including cryogenic storage and diagnostic reagents; and (6) diagnostic services through nearly 40 medical laboratories. The portfolio includes CALIBRA Precision Medicine subsidiary for clinical mass spectrometry, DIAN Biotechnology (GENEDIAN brand) for IVD products, DIAN Healthcare for health management, DIAN FORENSICS for forensic services, and cold chain logistics operations. The company serves over 22,000 medical institutions with over 4,500 diagnostic parameters.

Differentiator

Problem solved

Functional benefit

Brands

• GENEDIAN: International brand of DIAN Biotechnology for diagnostic products and services, operating in Europe, Australia and Southeast Asia.
• SayFine
• CALIBRA
• DIAN Healthcare
• DIAN FORENSICS
• Medical Mall

Products and services

• Medical Diagnostic Laboratory Services Outsourced clinical diagnostic testing services delivered through a national network of nearly 40 medical laboratories to hospitals, clinics, and medical institutions across China, with daily capacity of 250,000 samples.
• DP-TOF Nucleic Acid Mass Spectrometry Solution

Quantifiable outcome

• 45 million+ cervical cancer cell pathological tests and 15 million+ HPV DNA tests completed
• +3 more outcomes

Named customers5 records

Segments9 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature9 records

Partnerships

14 partnerships are on record, tiered minor, core and flagship.

• Gulf Medical UniversityminorStrategic or Co-development Partner · 17 January 2024Dian Diagnostics signed Letter of Intent for Cooperation with Gulf Medical University for academic and research collaboration.
• European MLM Medical LabminorStrategic or Co-development Partner · 7 May 2019Teddy Lab reached strategic cooperation with European MLM medical lab to contribute to international pharmaceutical research and development.
• University of Malaya Medical CentreminorStrategic or Co-development Partner · 31 March 2019Deepening and expanding international cooperation with medical centre visits and academic exchange.
• Zhejiang Pathology Specialty AllianceminorStrategic or Co-development Partner · 1 January 2019DIAN DIAGNOSTICS participated in the establishment of Zhejiang Pathology Specialty Alliance in 2019.
• Agena BiosciencecoreTechnology or Integration · 4 July 2018DIAN partnered with Agena for mass spectrometry platform development and applications in clinical diagnostics.
• Roche DiagnosticscoreStrategic or Co-development Partner · 1 January 2018DIAN joined hands with Roche Diagnostics to introduce comprehensive genome sequencing analysis service for jointly promoting the progression of individualized diagnosis and treatment of tumor in China.
• Foundation Medicine (FMI)coreTechnology or Integration · 1 January 2018DIAN joined hands with Roche and FMI to introduce comprehensive genome sequencing analysis service for tumor diagnosis and treatment in China.
• Zhejiang Laboratory and Testing Sharing Platform Specialty AllianceminorStrategic or Co-development Partner · 1 January 2018DIAN DIAGNOSTICS participated in the establishment of Zhejiang Laboratory and Testing Sharing Platform Specialty Alliance in 2019.
• Johns Hopkins University - International Pathology Consultation CentercoreStrategic or Co-development Partner · 1 January 2017International Pathology Consultation Center established for pathology consultation services bridging US and China expertise.
• Jiebai GroupcoreStrategic or Co-development Partner · 1 January 2016Three listed companies - DIAN DIAGNOSTICS, Jiebai Group and Baida Group - jointly established the Medical Mall, the first integrated health care and retail business mall in China.
• Baida GroupcoreStrategic or Co-development Partner · 1 January 2016Three listed companies - DIAN DIAGNOSTICS, Jiebai Group and Baida Group - jointly established the Medical Mall, the first integrated health care and retail business mall in China.
• Johns Hopkins UniversityflagshipStrategic or Co-development Partner · 1 January 2015DIAN DIAGNOSTICS jointly held the Dian-Hopkins Forum together with Johns Hopkins University six times since 2015. In 2017, DIAN DIAGNOSTICS established its International Pathology Consultation Center in collaboration with Johns Hopkins University for international pathology expertise sharing.
• SCIEX (Danaher Group)coreTechnology or IntegrationCALIBRA Precision Medicine, a subsidiary of DIAN DIAGNOSTICS, maintains close strategic cooperation with SCIEX, a global mass spectrometry leader. Together they work on R&D and production of clinical mass spectrometers and reagents, multi-omics innovation and other fields.
• PhenomenexcoreTechnology or IntegrationCALIBRA Precision Medicine maintains strategic cooperation with Phenomenex, a separation science and technology innovator, for clinical mass spectrometry R&D and production.

Scale indicators26 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Mindray: Largest Chinese medical device and IVD instrumentation manufacturer; overlaps with DIAN's IVD reagent and instrument business (PCR, mass spec, pathology scanners) as a broader incumbent with far greater scale.
• Sonic Healthcare: International medical diagnostics operator with lab networks across Australia, Europe, and the US; comparable in operating multi-country lab services and partnering with hospital systems, relevant to DIAN's international expansion strategy.
• Quest Diagnostics: Largest US independent clinical laboratory network with extensive routine and esoteric testing menus; comparable in scale and breadth of diagnostic services, with similar enterprise sales motion to hospitals and physicians.
• Laboratory Corporation of America (Labcorp): Global clinical laboratory and diagnostics company; comparable in central-lab operating model, breadth of test menu, and companion diagnostics capabilities competing for the same hospital outsourcing decisions.
• Shanghai Fosun Pharmaceutical (Diagnostics arm): Diversified Chinese healthcare conglomerate with a meaningful diagnostics and IVD business, comparable in offering integrated diagnostic services and products but operating across a much wider therapeutic footprint.

Others

• Agena Bioscience: Mass spectrometry platform provider for clinical genomics, already a partner of DIAN. Ecosystem participant and technology enabler rather than direct competitor, but relevant for benchmarking DIAN's DP-TOF and Agena-based assay strategy.

Direct peers

• KingMed Diagnostics: China's largest independent medical laboratory network, directly comparable in operating a national chain of clinical labs serving hospitals with routine and esoteric diagnostic testing. Closest domestic analog in business model and customer base.
• BGI Genomics: Global genomics and molecular diagnostics operator with strong NIPT, oncology, and infectious disease testing franchises. Overlaps with DIAN's sequencing-based oncology and maternal/child health diagnostics.
• DaAn Gene (Da An Gene): Leading Chinese molecular diagnostics company with PCR, NAAT, and clinical lab services across infectious disease and oncology. Directly competes with DIAN's molecular IVD and central lab offerings in China.

Emerging players

• WuXi Diagnostics: China-focused integrated diagnostics platform combining clinical labs with IVD R&D, comparable to DIAN's product+service model but with a younger footprint and stronger focus on hospital-side partnership models.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/dian-diagnostics-group-co.-ltd.

Compliance18 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DIAN DIAGNOSTICS GROUP CO., LTD.